Matt Phipps
Stock Analyst at William Blair
(0.13)
# 4,122
Out of 4,732 analysts
15
Total ratings
18.18%
Success rate
-44%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matt Phipps
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KROS Keros Therapeutics | Downgrades: Market Perform | n/a | $10.86 | - | 1 | Dec 12, 2024 | |
| UPB Upstream Bio | Initiates: Outperform | n/a | $11.00 | - | 1 | Nov 5, 2024 | |
| TENX Tenax Therapeutics | Initiates: Outperform | n/a | $6.37 | - | 1 | Sep 30, 2024 | |
| CGEM Cullinan Therapeutics | Initiates: Outperform | n/a | $10.26 | - | 1 | Apr 15, 2024 | |
| BMY Bristol-Myers Squibb Company | Downgrades: Market Perform | n/a | $56.29 | - | 1 | Oct 27, 2023 | |
| KZR Kezar Life Sciences | Downgrades: Market Perform | n/a | $6.19 | - | 2 | Mar 16, 2023 | |
| JANX Janux Therapeutics | Initiates: Outperform | n/a | $40.72 | - | 1 | Nov 14, 2022 | |
| GMAB Genmab | Initiates: Market Perform | n/a | $20.80 | - | 1 | Nov 14, 2022 | |
| INKT MiNK Therapeutics | Initiates: Outperform | n/a | $0.88 | - | 1 | Nov 9, 2021 | |
| TPST Tempest Therapeutics | Initiates: Outperform | n/a | $0.93 | - | 1 | Oct 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $5.51 | - | 1 | Oct 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $140.55 | - | 2 | Jun 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $39.45 | - | 1 | Apr 8, 2021 |
Keros Therapeutics
Dec 12, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $10.86
Upside: -
Upstream Bio
Nov 5, 2024
Initiates: Outperform
Price Target: n/a
Current: $11.00
Upside: -
Tenax Therapeutics
Sep 30, 2024
Initiates: Outperform
Price Target: n/a
Current: $6.37
Upside: -
Cullinan Therapeutics
Apr 15, 2024
Initiates: Outperform
Price Target: n/a
Current: $10.26
Upside: -
Bristol-Myers Squibb Company
Oct 27, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $56.29
Upside: -
Kezar Life Sciences
Mar 16, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $6.19
Upside: -
Janux Therapeutics
Nov 14, 2022
Initiates: Outperform
Price Target: n/a
Current: $40.72
Upside: -
Genmab
Nov 14, 2022
Initiates: Market Perform
Price Target: n/a
Current: $20.80
Upside: -
MiNK Therapeutics
Nov 9, 2021
Initiates: Outperform
Price Target: n/a
Current: $0.88
Upside: -
Tempest Therapeutics
Oct 21, 2021
Initiates: Outperform
Price Target: n/a
Current: $0.93
Upside: -
Oct 21, 2021
Initiates: Outperform
Price Target: n/a
Current: $5.51
Upside: -
Jun 8, 2021
Upgrades: Outperform
Price Target: n/a
Current: $140.55
Upside: -
Apr 8, 2021
Initiates: Outperform
Price Target: n/a
Current: $39.45
Upside: -